Study to Evaluate the Safety of Nanoxel M Inj.

Samyang Biopharmaceuticals Corporation1,498 enrolled

Overview

Study to evaluate the safety of Nanoxel M inj. administration in patients.

This is a multi-center, prospective observational study to observe the incidence of adverse events under actual clinical settings to test the safety of Nanoxel-M inj. administration in patients with breast cancer, non-small cell lung cancer, prostate cancer, ovarian cancer, head \& neck cancer, gastric cancer or esophageal cancer.

Study Type

OBSERVATIONAL

Enrollment

1,498

Conditions

Breast Cancer Non-small Cell Lung Cancer Prostate Cancer Ovarian Cancer Head and Neck Cancer Gastric Cancer Esophageal Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Adults ≥18 years old 2. Patients who have signed written consent form prior to participating in the clinical trial 3. Patients who are assessed as adequate to administer Nanoxel M injection. Exclusion Criteria: 1\) Patients who have shown severe hypersensitivity to Docetaxel and concomitant drugs

Locations (1)

Samyang Biopharmaceuticals

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Safety of Nanoxel M inj.

The incidence of Treatment-Emergent Adverse Event

Time frame: through study completion, an average of 6cycles(each cycle is 3weeks)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.